from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine etteurs
Combination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and median progressionfree survival of 10.9 months
Liège, Belgium, and Grenoble, France, April 8, 2024 – PDC*line Pharma, a clinicalstage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.